Yeah, here is an old post copied here of my rough estimating potential market if leronlimab proves to be effective against ccr5 moderately positive cancers (ccr5 strong positive would be less if that is the population ~15%-20% maybe instead of 50%), not including other MOA we listed like for example those cancers that are not ccr5+, but surrounding TAMs are, which leronlimab might help. I don't believe it will be a magic bullet for all cancers in all situations and cancer might find a way around eventually as it always seem to do (with more than one unique pathway), for example people without ccr5 expression die of cancer. But I would not be surprised if it ends up extending the life of many people with many different cancer types. All,imo.

https://investorshangout.com/post/view?id=5596806

Link to cancers and ccr5 in previous post I replied to here, just rough estimating,

Quote:

---

Metastasis is believed to be the cause of up to 90 percent of cancer deaths.

---

https://www.sciencedaily.com/releases/2019/05...112734.htm


Also depending on cancer, looks like 25%-75% can be high ccr5 expressing, from these links, so say 50%.

US deaths 352k per year from these, see below

352k cancer deaths x 90% death from metastasis x 50% ccr5+ in metastatic

gives

160k deaths per year which leronlimab might help save or extend life for a good number of these in US alone. I know we just have data on the one patient, but the possibilities here with this is truly amazing.

Of course if it works for a percentage these 160k, they wont stop there, it will probably be moved to earlier stages.



pancreatic, prostate, lung, breast, liver and melanoma cancers

1) Breast Cancer New Cases: 271k Deaths: 42k
2) Lung New Cases: 228k Deaths: 143k
3) Prostate New Cases: 175k Deaths: 32k
4)Colorectal New Cases: 146k Deaths: 51k
5) Melanoma New Cases: 96k Deaths: 7k
11) Pancreatic New Cases: 57k Deaths: 46k
13) LiverNew Cases: 42k Deaths: 31k